{"transactions":[{"id":729038,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:17:39.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":39000,"derivative":{"underlying":"Common stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001439222-26-000089","document":"wk-form4_1782249456.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000089/wk-form4_1782249456.xml","form_type":"4"}},{"id":729037,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:17:39.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":39000,"derivative":{"underlying":"Common stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001439222-26-000089","document":"wk-form4_1782249456.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000089/wk-form4_1782249456.xml","form_type":"4"}},{"id":743100,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T23:02:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":13300,"derivative":{"exercise_price":12.89,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001193125-26-266236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266236/ownership.xml","form_type":"4"}},{"id":743099,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T23:02:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":32609,"source":{"system":"sec-edgar","filing":"0001193125-26-266236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266236/ownership.xml","form_type":"4"}},{"id":814393,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":40500,"derivative":{"underlying":"Common stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814392,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":25528},"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814391,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":6596,"price":34.71,"value":228947.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":184508,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814390,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":191104,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814389,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":12472,"price":34.71,"value":432903.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022."}],"balance_after":177604,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814388,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":190076,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":866588,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":26000,"derivative":{"underlying":"Common stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866587,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":18000,"derivative":{"underlying":"Common stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866586,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866585,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":174000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":174000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":174000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866584,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":48000,"derivative":{"underlying":"Common stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866583,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5918,"price":28.96,"value":171385.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":164548,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866582,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":170466,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866581,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":8267,"price":28.96,"value":239412.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":157466,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866580,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":165733,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866579,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3870,"price":28.96,"value":112075.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":147733,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866578,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":151603,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":955126,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":12750},"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":955125,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":false,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":25528,"derivative":{"underlying":"Common stock","underlying_shares":25528},"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":955124,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":6230,"price":27.09,"value":168770.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":143103,"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":955123,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":149333,"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":955122,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"sale","planned":true,"acquired":false,"shares":12473,"price":27.09,"value":337893.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022."}],"balance_after":136583,"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":955121,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-01-03T01:16:10.000Z","date":"2025-12-30","kind":"exercise","planned":true,"acquired":true,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":149056,"source":{"system":"sec-edgar","filing":"0001439222-26-000008","document":"wk-form4_1767402967.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000008/wk-form4_1767402967.xml","form_type":"4"}},{"id":1068802,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2025-08-12T20:24:24.000Z","date":"2025-08-08","kind":"exercise","planned":true,"acquired":false,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":22691},"source":{"system":"sec-edgar","filing":"0001439222-25-000093","document":"wk-form4_1755030260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000093/wk-form4_1755030260.xml","form_type":"4"}},{"id":1068801,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-08-12T20:24:24.000Z","date":"2025-08-08","kind":"sale","planned":true,"acquired":false,"shares":11085,"price":36.67,"value":406486.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022."}],"balance_after":123528,"source":{"system":"sec-edgar","filing":"0001439222-25-000093","document":"wk-form4_1755030260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000093/wk-form4_1755030260.xml","form_type":"4"}},{"id":1068800,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-08-12T20:24:24.000Z","date":"2025-08-08","kind":"exercise","planned":true,"acquired":true,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":134613,"source":{"system":"sec-edgar","filing":"0001439222-25-000093","document":"wk-form4_1755030260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000093/wk-form4_1755030260.xml","form_type":"4"}},{"id":1101010,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":false,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":12750,"derivative":{"underlying":"Common stock","underlying_shares":12750},"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1101009,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":false,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on June 24, 2025, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":51056,"derivative":{"underlying":"Common stock","underlying_shares":25527},"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1101008,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"sale","planned":true,"acquired":false,"shares":6229,"price":33.54,"value":208920.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2023."}],"balance_after":111922,"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1101007,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":true,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":118151,"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1101006,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"sale","planned":true,"acquired":false,"shares":12471,"price":33.54,"value":418277.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022."}],"balance_after":105401,"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1101005,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-06-26T21:22:05.000Z","date":"2025-06-24","kind":"exercise","planned":true,"acquired":true,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":117872,"source":{"system":"sec-edgar","filing":"0001439222-25-000063","document":"wk-form4_1750972918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000063/wk-form4_1750972918.xml","form_type":"4"}},{"id":1111609,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:38.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":11450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":11450,"derivative":{"exercise_price":8.37,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":11450},"source":{"system":"sec-edgar","filing":"0000950170-25-086271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086271/ownership.xml","form_type":"4"}},{"id":1111608,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:38.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":23409,"source":{"system":"sec-edgar","filing":"0000950170-25-086271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025086271/ownership.xml","form_type":"4"}},{"id":1227872,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":36000,"derivative":{"underlying":"Common stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227871,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227870,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (right to buy)","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":142500,"derivative":{"exercise_price":35.54,"expiration_date":"2035-03-01","underlying":"Common stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227869,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"grant","planned":true,"acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":39000,"derivative":{"underlying":"Common stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227868,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":8794,"price":35.54,"value":312538.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":92345,"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227867,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101139,"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227866,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":4153,"price":35.54,"value":147597.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":83139,"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1227865,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-03-04T21:10:25.000Z","date":"2025-03-01","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":87292,"source":{"system":"sec-edgar","filing":"0001439222-25-000015","document":"wk-form4_1741122616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000015/wk-form4_1741122616.xml","form_type":"4"}},{"id":1435915,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2024-08-12T21:15:31.000Z","date":"2024-08-08","kind":"exercise","planned":true,"acquired":false,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":22691,"derivative":{"underlying":"Common stock","underlying_shares":22691},"source":{"system":"sec-edgar","filing":"0001439222-24-000123","document":"wk-form4_1723497325.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000123/wk-form4_1723497325.xml","form_type":"4"}},{"id":1435914,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-08-12T21:15:31.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":11091,"price":42.75,"value":474140.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022."}],"balance_after":78792,"source":{"system":"sec-edgar","filing":"0001439222-24-000123","document":"wk-form4_1723497325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000123/wk-form4_1723497325.xml","form_type":"4"}},{"id":1435913,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-08-12T21:15:31.000Z","date":"2024-08-08","kind":"exercise","planned":true,"acquired":true,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":89883,"source":{"system":"sec-edgar","filing":"0001439222-24-000123","document":"wk-form4_1723497325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000123/wk-form4_1723497325.xml","form_type":"4"}},{"id":1477304,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T21:14:33.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":22297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 13, 2024 with respect to 22,297 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on June 13, 2025 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter."}],"balance_after":22297,"derivative":{"exercise_price":25.96,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":22297},"source":{"system":"sec-edgar","filing":"0000950170-24-074383","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024074383/ownership.xml","form_type":"4"}},{"id":1477303,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T21:14:33.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":15409,"source":{"system":"sec-edgar","filing":"0000950170-24-074383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024074383/ownership.xml","form_type":"4"}},{"id":1486628,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2024-06-07T20:25:21.000Z","date":"2024-06-05","kind":"exercise","planned":true,"acquired":false,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":76583,"derivative":{"underlying":"Common stock","underlying_shares":25527},"source":{"system":"sec-edgar","filing":"0001439222-24-000073","document":"wk-form4_1717791913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000073/wk-form4_1717791913.xml","form_type":"4"}},{"id":1486627,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-06-07T20:25:21.000Z","date":"2024-06-05","kind":"sale","planned":true,"acquired":false,"shares":12115,"price":48.84,"value":591696.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022."}],"balance_after":67192,"source":{"system":"sec-edgar","filing":"0001439222-24-000073","document":"wk-form4_1717791913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000073/wk-form4_1717791913.xml","form_type":"4"}},{"id":1486626,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-06-07T20:25:21.000Z","date":"2024-06-05","kind":"exercise","planned":true,"acquired":true,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":79307,"source":{"system":"sec-edgar","filing":"0001439222-24-000073","document":"wk-form4_1717791913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000073/wk-form4_1717791913.xml","form_type":"4"}},{"id":1595534,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:10:31.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":17000,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-24-000048","document":"wk-form4_1709673014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000048/wk-form4_1709673014.xml","form_type":"4"}},{"id":1595533,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (right to buy)","published_at":"2024-03-05T21:10:31.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":195500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":195500,"derivative":{"exercise_price":32.27,"expiration_date":"2034-03-01","underlying":"Common stock","underlying_shares":195500},"source":{"system":"sec-edgar","filing":"0001439222-24-000048","document":"wk-form4_1709673014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000048/wk-form4_1709673014.xml","form_type":"4"}},{"id":1595532,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2024-03-05T21:10:31.000Z","date":"2024-03-01","kind":"grant","planned":true,"acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":54000,"derivative":{"underlying":"Common stock","underlying_shares":54000},"source":{"system":"sec-edgar","filing":"0001439222-24-000048","document":"wk-form4_1709673014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000048/wk-form4_1709673014.xml","form_type":"4"}},{"id":1595531,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:10:31.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":4156,"price":32.57,"value":135360.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":53780,"source":{"system":"sec-edgar","filing":"0001439222-24-000048","document":"wk-form4_1709673014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000048/wk-form4_1709673014.xml","form_type":"4"}},{"id":1595530,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-03-05T21:10:31.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":57936,"source":{"system":"sec-edgar","filing":"0001439222-24-000048","document":"wk-form4_1709673014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000048/wk-form4_1709673014.xml","form_type":"4"}},{"id":1671967,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2024-01-24T21:20:32.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":false,"shares":17018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":102110,"derivative":{"underlying":"Common stock","underlying_shares":17018},"source":{"system":"sec-edgar","filing":"0001439222-24-000014","document":"wk-form4_1706131222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000014/wk-form4_1706131222.xml","form_type":"4"}},{"id":1671966,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:20:32.000Z","date":"2024-01-24","kind":"sale","planned":true,"acquired":false,"shares":7635,"price":21.64,"value":165221.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022."}],"balance_after":49436,"source":{"system":"sec-edgar","filing":"0001439222-24-000014","document":"wk-form4_1706131222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000014/wk-form4_1706131222.xml","form_type":"4"}},{"id":1671965,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-01-24T21:20:32.000Z","date":"2024-01-20","kind":"exercise","planned":true,"acquired":true,"shares":17018,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":57071,"source":{"system":"sec-edgar","filing":"0001439222-24-000014","document":"wk-form4_1706131222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000014/wk-form4_1706131222.xml","form_type":"4"}},{"id":1682605,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2024-01-09T21:28:28.000Z","date":"2024-01-05","kind":"exercise","planned":true,"acquired":false,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on  January 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on  January 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":119128,"derivative":{"underlying":"Common stock","underlying_shares":25527},"source":{"system":"sec-edgar","filing":"0001439222-24-000010","document":"wk-form4_1704835697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000010/wk-form4_1704835697.xml","form_type":"4"}},{"id":1682604,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-01-09T21:28:28.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":12066,"price":22.99,"value":277397.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022."}],"balance_after":40053,"source":{"system":"sec-edgar","filing":"0001439222-24-000010","document":"wk-form4_1704835697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000010/wk-form4_1704835697.xml","form_type":"4"}},{"id":1682603,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-01-09T21:28:28.000Z","date":"2024-01-05","kind":"exercise","planned":true,"acquired":true,"shares":25527,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52119,"source":{"system":"sec-edgar","filing":"0001439222-24-000010","document":"wk-form4_1704835697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000010/wk-form4_1704835697.xml","form_type":"4"}},{"id":1810789,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2023-08-10T20:07:15.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":false,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":45382,"derivative":{"underlying":"Common stock","underlying_shares":22691},"source":{"system":"sec-edgar","filing":"0001439222-23-000123","document":"wk-form4_1691698025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000123/wk-form4_1691698025.xml","form_type":"4"}},{"id":1810788,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-08-10T20:07:15.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":10178,"price":25.48,"value":259335.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units."}],"balance_after":26592,"source":{"system":"sec-edgar","filing":"0001439222-23-000123","document":"wk-form4_1691698025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000123/wk-form4_1691698025.xml","form_type":"4"}},{"id":1810787,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-08-10T20:07:15.000Z","date":"2023-08-08","kind":"exercise","planned":true,"acquired":true,"shares":22691,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36770,"source":{"system":"sec-edgar","filing":"0001439222-23-000123","document":"wk-form4_1691698025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000123/wk-form4_1691698025.xml","form_type":"4"}},{"id":1841017,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2023-06-30T20:05:19.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":false,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":144655,"derivative":{"underlying":"Common stock","underlying_shares":25528},"source":{"system":"sec-edgar","filing":"0001439222-23-000103","document":"wk-form4_1688155500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000103/wk-form4_1688155500.xml","form_type":"4"}},{"id":1841016,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:05:19.000Z","date":"2023-06-30","kind":"sale","planned":true,"acquired":false,"shares":11449,"price":28.36,"value":324693.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units."}],"balance_after":14079,"source":{"system":"sec-edgar","filing":"0001439222-23-000103","document":"wk-form4_1688155500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000103/wk-form4_1688155500.xml","form_type":"4"}},{"id":1841015,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-06-30T20:05:19.000Z","date":"2023-06-28","kind":"exercise","planned":true,"acquired":true,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25528,"source":{"system":"sec-edgar","filing":"0001439222-23-000103","document":"wk-form4_1688155500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000103/wk-form4_1688155500.xml","form_type":"4"}},{"id":1972878,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (right to buy)","published_at":"2023-03-03T21:06:20.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":94500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":94500,"derivative":{"exercise_price":25.01,"expiration_date":"2033-03-01","underlying":"Common stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001439222-23-000048","document":"wf-form4_167787754123125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000048/wf-form4_167787754123125.xml","form_type":"4"}},{"id":1972877,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2023-03-03T21:06:20.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on  March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":25500,"derivative":{"underlying":"Common stock","underlying_shares":25500},"source":{"system":"sec-edgar","filing":"0001439222-23-000048","document":"wf-form4_167787754123125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000048/wf-form4_167787754123125.xml","form_type":"4"}},{"id":2190811,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2022-08-09T20:50:33.000Z","date":"2022-08-08","kind":"grant","acquired":true,"shares":68073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":68073,"derivative":{"underlying":"Common stock","underlying_shares":68073},"source":{"system":"sec-edgar","filing":"0001439222-22-000074","document":"wf-form4_166007821499099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000074/wf-form4_166007821499099.xml","form_type":"4"}},{"id":2190810,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-08-09T20:50:33.000Z","date":"2022-08-08","kind":"grant","acquired":true,"shares":561083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":561083,"derivative":{"exercise_price":29.38,"expiration_date":"2032-08-08","underlying":"Common stock","underlying_shares":561083},"source":{"system":"sec-edgar","filing":"0001439222-22-000074","document":"wf-form4_166007821499099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000074/wf-form4_166007821499099.xml","form_type":"4"}},{"id":2626553,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-07-23T16:42:07.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":21750,"price":100.14,"value":2178045.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":100.14,"exercise_date":"2018-06-07","expiration_date":"2027-06-07","underlying":"Common Stock, par value $.0001 per share","underlying_shares":21750},"source":{"system":"sec-edgar","filing":"0000899866-21-000069","document":"wf-form4_162707291289703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000069/wf-form4_162707291289703.xml","form_type":"4"}},{"id":2626552,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-07-23T16:42:07.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":150832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC.  In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899866-21-000069","document":"wf-form4_162707291289703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000069/wf-form4_162707291289703.xml","form_type":"4"}},{"id":2632529,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-07-16T16:43:30.000Z","date":"2021-07-14","kind":"grant","acquired":true,"shares":29501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied.  These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan."}],"balance_after":150832,"source":{"system":"sec-edgar","filing":"0000899866-21-000051","document":"wf-form4_162646819566694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000051/wf-form4_162646819566694.xml","form_type":"4"}},{"id":2632528,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-07-16T16:43:30.000Z","date":"2021-07-14","kind":"grant","acquired":true,"shares":30643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied.  These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan."}],"balance_after":121331,"source":{"system":"sec-edgar","filing":"0000899866-21-000051","document":"wf-form4_162646819566694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000051/wf-form4_162646819566694.xml","form_type":"4"}},{"id":2676496,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-06-09T16:52:33.000Z","date":"2021-06-08","kind":"tax_withholding","acquired":false,"shares":1086,"price":177,"value":192222.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":90688,"source":{"system":"sec-edgar","filing":"0000899866-21-000049","document":"wf-form4_162327193288127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000049/wf-form4_162327193288127.xml","form_type":"4"}},{"id":2822832,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-03-02T17:55:59.000Z","date":"2021-02-28","kind":"grant","acquired":true,"shares":24473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":91774,"source":{"system":"sec-edgar","filing":"0000899866-21-000026","document":"wf-form4_161472574182653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000026/wf-form4_161472574182653.xml","form_type":"4"}},{"id":2938555,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-12-18T17:09:35.000Z","date":"2020-12-16","kind":"tax_withholding","acquired":false,"shares":3261,"price":157.96,"value":515107.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":67301,"source":{"system":"sec-edgar","filing":"0000899866-20-000095","document":"wf-form4_160832936211224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000095/wf-form4_160832936211224.xml","form_type":"4"}},{"id":2938554,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-12-18T17:09:35.000Z","date":"2020-12-16","kind":"tax_withholding","acquired":false,"shares":18134,"price":157.96,"value":2864446.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."}],"balance_after":70562,"source":{"system":"sec-edgar","filing":"0000899866-20-000095","document":"wf-form4_160832936211224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000095/wf-form4_160832936211224.xml","form_type":"4"}},{"id":2938553,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-12-18T17:09:35.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":40677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan."}],"balance_after":88696,"source":{"system":"sec-edgar","filing":"0000899866-20-000095","document":"wf-form4_160832936211224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000095/wf-form4_160832936211224.xml","form_type":"4"}},{"id":3117534,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-06-09T16:58:39.000Z","date":"2020-06-08","kind":"tax_withholding","acquired":false,"shares":1642,"price":114.61,"value":188189.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":48019,"source":{"system":"sec-edgar","filing":"0000899866-20-000062","document":"wf-form4_159173630026912.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000062/wf-form4_159173630026912.xml","form_type":"4"}},{"id":3234894,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-03-03T18:18:38.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":1401,"price":90.54,"value":126846.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":49661,"source":{"system":"sec-edgar","filing":"0000899866-20-000019","document":"wf-form4_158327748870501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000019/wf-form4_158327748870501.xml","form_type":"4"}},{"id":3234893,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-03-03T18:18:38.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":10880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":51062,"source":{"system":"sec-edgar","filing":"0000899866-20-000019","document":"wf-form4_158327748870501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000019/wf-form4_158327748870501.xml","form_type":"4"}},{"id":3283190,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-02-10T16:58:52.000Z","date":"2020-02-07","kind":"tax_withholding","acquired":false,"shares":1594,"price":102.97,"value":164134.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $102.97 - $103.24.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":40182,"source":{"system":"sec-edgar","filing":"0000899866-20-000015","document":"wf-form4_158137191608200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000015/wf-form4_158137191608200.xml","form_type":"4"}},{"id":3494877,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-06-11T18:38:34.000Z","date":"2019-06-07","kind":"tax_withholding","acquired":false,"shares":1643,"price":118.61,"value":194876.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":41776,"source":{"system":"sec-edgar","filing":"0000899866-19-000076","document":"wf-form4_156029269946793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000076/wf-form4_156029269946793.xml","form_type":"4"}},{"id":3615635,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-03-05T20:19:44.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":9428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":43419,"source":{"system":"sec-edgar","filing":"0000899866-19-000049","document":"wf-form4_155183517005730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000049/wf-form4_155183517005730.xml","form_type":"4"}},{"id":3620728,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-03-04T17:36:35.000Z","date":"2019-02-28","kind":"tax_withholding","acquired":false,"shares":670,"price":132.93,"value":89063.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $134.96.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":33991,"source":{"system":"sec-edgar","filing":"0000899866-19-000037","document":"wf-form4_155173898108036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000037/wf-form4_155173898108036.xml","form_type":"4"}},{"id":3666574,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-02-11T18:20:20.000Z","date":"2019-02-07","kind":"tax_withholding","acquired":false,"shares":1596,"price":119.57,"value":190833.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $119.43 - $119.57.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":34661,"source":{"system":"sec-edgar","filing":"0000899866-19-000012","document":"wf-form4_154992720701029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000012/wf-form4_154992720701029.xml","form_type":"4"}},{"id":3897511,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-06-12T16:51:25.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":1645,"price":118.53,"value":194981.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."}],"balance_after":36257,"source":{"system":"sec-edgar","filing":"0000899866-18-000102","document":"wf-form4_152883666838735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000102/wf-form4_152883666838735.xml","form_type":"4"}},{"id":4021786,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-03-02T17:00:09.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":8940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":37902,"source":{"system":"sec-edgar","filing":"0000899866-18-000058","document":"wf-form4_152002798864307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000058/wf-form4_152002798864307.xml","form_type":"4"}},{"id":4071056,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:17:51.000Z","date":"2018-02-08","kind":"sale","acquired":false,"shares":1651,"price":116.31,"value":192027.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":28962,"source":{"system":"sec-edgar","filing":"0000899866-18-000042","document":"wf-form4_151813545767461.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000042/wf-form4_151813545767461.xml","form_type":"4"}},{"id":4071055,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-02-08T19:17:51.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":15894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 15,894 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary"}],"balance_after":30613,"source":{"system":"sec-edgar","filing":"0000899866-18-000042","document":"wf-form4_151813545767461.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000042/wf-form4_151813545767461.xml","form_type":"4"}},{"id":4287612,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-06-09T18:35:29.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":21750,"price":100.14,"value":2178045.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Stock Options under the 2017 Incentive Plan.  25% vest on the 1-year anniversary of the grant date, and 1/16 vest every 90 days thereafter."}],"balance_after":21750,"derivative":{"exercise_price":100.14,"exercise_date":"2018-06-07","expiration_date":"2027-06-07","underlying":"Common Stock, par value $.0001 per share","underlying_shares":21750},"source":{"system":"sec-edgar","filing":"0000899866-17-000136","document":"wf-form4_149704771327359.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000136/wf-form4_149704771327359.xml","form_type":"4"}},{"id":4287611,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Commercial Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-06-09T18:35:29.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":14719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vest on each anniversary of the grant date."}],"balance_after":14719,"source":{"system":"sec-edgar","filing":"0000899866-17-000136","document":"wf-form4_149704771327359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000136/wf-form4_149704771327359.xml","form_type":"4"}}]}